Impact ledger
Eli Lilly and Company (LLY): the developments shaping its investment case
Follow the evidence affecting Eli Lilly and Company's margins, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Eli Lilly and Company · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-28 · 4 reports
Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation
Channel: Strategic R&D reallocation, pipeline efficiency, and market perception of future growth drivers.
mixed· 1-3m
2026-09-28
Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations
Channel: Strategic capital allocation, R&D efficiency, pipeline optimization
Bullish· 1-3m
2026-09-28 · 2 reports
Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead
Channel: Pipeline rationalization, R&D efficiency, investor perception of future growth drivers.
mixed· 1-3m
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-06 | margin | Bullish | Surging demand for high-margin GLP-1 agonists (Mounjaro/Zepbound) is driving margin expansion and earnings revisions. |
| 2026-07-22 | revenue | Bullish | Expansion of GLP-1 TAM into alcohol use disorder treatment. |
| 2026-07-13 | revenue | Bullish | Company raised 2026 guidance to $82-85B based on Mounjaro and Zepbound growth. |
| 2026-06-17 | revenue | Bullish | GLP-1 market projected to reach $95.3B by 2035 with a 12.1% CAGR, driven by oral formulations. |
| 2026-06-12 | share_count | Bullish | Stock component of consideration dilutes existing acquirer holders. |
| 2026-06-12 | net_debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. |
| 2026-06-12 | revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. |
Event impact log
126 events mapped to LLY since 2026-08-18. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Increased competition in the NSCLC market, potentially impacting future market share for their oncology portfolio. | Bearish | 1-3m | 0.30 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | Increased competition in the non-small cell lung cancer (NSCLC) market, particularly for patients with MET-driven resistance. | watch | 1-5y | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation | Strategic R&D reallocation, pipeline efficiency, and market perception of future growth drivers. | mixed | 1-3m | 0.70 |
| 2026-09-28 | HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Potential future competitive pressure in the oncology market, particularly for KRAS-mutated and EGFR-driven solid tumors. | watch | 1-5y | 0.20 |
| 2026-09-28 | Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review | Direct impact on pipeline value and R&D efficiency perception. Potential reallocation of R&D resources. | mixed | 1-3m | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy Review | Strategic pipeline optimization, reallocation of R&D resources to higher-potential assets, reduced future R&D expenditure on a low-probability candidate. | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | Potential future competition in oncology, particularly in solid tumors, if HMPL-A830 progresses. | watch | 1-5y | 0.10 |
| 2026-09-28 | Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead | Pipeline rationalization, R&D efficiency, investor perception of future growth drivers. | mixed | 1-3m | 0.40 |
| 2026-09-28 | Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review | Investor sentiment regarding pipeline depth and R&D efficiency; reallocation of R&D resources. | mixed | 1-3m | 0.30 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales | Strategic focus, R&D efficiency, revenue concentration risk management | mixed | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy | Potential future competitive pressure in the oncology market, specifically for KRAS and EGFR targeted therapies. Successful development could introduce a new competitor. | watch | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations | Strategic capital allocation, R&D efficiency, pipeline optimization | Bullish | 1-3m | 0.70 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy Data | Strategic R&D allocation, reduced future R&D expense, increased focus on successful pipeline assets, and maintaining high efficacy standards for commercialized products. | Bullish | 1-3m | 0.70 |
| 2026-09-27 | Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total Revenue | Direct impact on R&D pipeline and investor sentiment regarding future growth drivers. Reinforces reliance on existing blockbuster drugs. | mixed | 1-3m | 0.60 |
| 2026-09-27 | Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% Revenue | Direct impact on future pipeline strength and investor sentiment regarding long-term growth sustainability. While current sales are strong, future growth relies on pipeline success. | mixed | 3-12m | 0.60 |
| 2026-09-27 | Eli Lilly discontinues developmental obesity drug over unmet efficacy threshold | Reduced future revenue potential from a specific pipeline asset, but also reduced R&D expenditure and potential for reallocation of resources to more promising candidates. Increased focus on existing commercial successes and other pipeline assets. | mixed | 1-3m | 0.60 |
| 2026-09-27 | Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm | Potential for enhanced drug discovery and development efficiency through advanced computational methods, including peptide design. | Bullish | 3-12m | 0.30 |
| 2026-09-27 | Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue | Pipeline rationalization, increased focus on core high-performing assets, and potential reallocation of R&D resources to more promising candidates or existing GLP-1 production. | Bullish | 1-3m | 0.70 |
| 2026-09-27 | Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy Standards | Strategic capital allocation and R&D efficiency. While a discontinuation, it signals a disciplined approach to pipeline management, focusing resources on more promising candidates or existing blockbusters. This could be viewed positively by investors as it avoids future sunk costs on a less effectiv | Bullish | 1-3m | 0.60 |
| 2026-09-25 | Pfizer and Nvidia Back $80M AI Computational Immunology Venture | Broader industry trend of increased investment in AI for drug discovery, potentially impacting R&D strategies and competitive dynamics for all major pharmaceutical companies. | watch | 1-3m | 0.30 |
| 2026-09-25 | Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JV | Broader industry trend towards AI in drug discovery, potentially increasing R&D efficiency for competitors and setting new industry standards. | watch | 3-12m | 0.30 |
| 2026-09-25 | Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant Discovery | As a major pharmaceutical company with significant R&D investment, Eli Lilly could benefit from the broader trend of AI adoption in drug discovery, potentially improving R&D efficiency and pipeline productivity. | Bullish | 1-5y | 0.30 |
| 2026-09-24 | Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder | Potential competitive landscape shift in mental health therapeutics. Lilly has a strong neuroscience pipeline and may be interested in or impacted by new treatments for anxiety disorders. | watch | 3-12m | 0.10 |
| 2026-09-24 | InnoCare and Eli Lilly Enter Strategic Licensing Deal with Up to $3.35B in Milestones | Strategic collaboration to expand early-stage drug pipeline, potentially leading to future revenue streams and reduced R&D costs for specific targets. | Bullish | 3-12m | 0.60 |
| 2026-09-24 | Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress | Increased competition in the NSCLC market, particularly for EGFR-mutated, MET-driven tumors, potentially impacting future market share for their oncology pipeline assets. | watch | 1-5y | 0.30 |
| 2026-09-24 | HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO | Increased competitive pressure in the EGFR-mutated NSCLC market, particularly for patients developing MET-driven resistance, potentially impacting future market share for competing therapies. | Bearish | 3-12m | 0.30 |
| 2026-09-24 | InnoCare and Eli Lilly Enter Strategic Licensing Deal Worth Up to $3.35B | Strategic pipeline enhancement through external innovation, potential for future revenue streams from new drug candidates. | Bullish | 3-12m | 0.60 |
| 2026-09-24 | InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billion | Eli Lilly gains access to potential novel drug candidates and discovery platforms, broadening its early-stage pipeline without the full upfront R&D investment. This could lead to future revenue streams if successful. | Bullish | 3-12m | 0.60 |
| 2026-09-24 | Eli Lilly Signs Up to $3.35B Drug Discovery Deal With InnoCare | Strategic collaboration to expand drug discovery pipeline, potentially leading to future revenue streams from novel therapies. | Bullish | 1-5y | 0.60 |
| 2026-09-24 | Eli Lilly and InnoCare Enter Collaboration Agreement Valued Up to $3.35B | Strategic R&D expansion and pipeline diversification through external collaboration. Potential for future revenue streams from successful drug development. | Bullish | 1-5y | 0.60 |
| 2026-09-23 | Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly | Increased direct competition in the GLP-1 weight-loss market, particularly from a new oral formulation with a potentially aggressive pricing strategy. | Bearish | 3-12m | 0.70 |
| 2026-09-23 | Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push | Increased direct competition in the lucrative obesity market, potential pricing pressure. | Bearish | 1-5y | 0.70 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide | Increased competitive pressure in the GLP-1/GIP market, potentially impacting future market share and pricing power for existing and pipeline assets. | mixed | 3-12m | 0.60 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide | Increased future competition in the GLP-1/GIP agonist market, potentially impacting market share and pricing power for existing and pipeline products. | Bearish | 1-5y | 0.70 |
| 2026-09-23 | Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share Defense | Increased competitive pressure in the GLP-1 market. Novo's oral formulation and volume pricing could challenge Lilly's market share and pricing power. | Bearish | 1-3m | 0.70 |
| 2026-09-21 | Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD | Potential future competition in the ADHD market, particularly for novel mechanisms of action. | watch | 1-5y | 0.20 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | Indirect impact through partnership agreements and potential milestone payments or royalty streams from Ionis's ASO assets. | watch | 3-12m | 0.10 |
| 2026-09-20 | Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal | Enhanced drug discovery capabilities, potential for accelerated R&D, access to novel data for AI-driven drug development. | Bullish | 3-12m | 0.60 |
| 2026-09-20 | Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact | Enhanced R&D capabilities, potential for accelerated drug discovery, improved R&D efficiency. | Bullish | 3-12m | 0.30 |
| 2026-09-19 | Teva presents real-world data showing UZEDY treatment continuity advantage | Similar to J&J, Eli Lilly has products in the broader neuroscience and psychiatric space (e.g., Zyprexa Relprevv, although less prominent than J&J's LAIs). Strong performance by UZEDY could contribute to a more competitive landscape, potentially influencing future market dynamics or R&D investment d | watch | 3-12m | 0.10 |
Continue this research
Build your Eli Lilly and Company investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the LLY entity page →